Duan Xiaojiao, Wu Jiarui, Huang Xingyue, Wang Kaihuan, Zhao Yi, Zhang Dan, Liu Xinkui, Zhang Xiaomeng
Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China.
Evid Based Complement Alternat Med. 2018 Jul 17;2018:7942936. doi: 10.1155/2018/7942936. eCollection 2018.
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) imposes a huge economic burden on healthcare systems worldwide. Chinese herbal injections (CHIs) are widely used to treat AECOPD. In this study, we examined the efficacy of CHIs in the treatment of AECOPD using a network meta-analysis (NMA).
Literature search was conducted from electronic databases of randomized controlled trials (RCTs) on CHIs plus Western medicine (WM) versus WM. WinBUGS 1.4.3 and STATA 12.0 were adopted to compute calculations and prepare graphs, respectively.
We included 155 RCTs with 13,218 patients. The results revealed that Danhong injection (DH) + WM had the greatest therapeutic potential in terms of rate of clinical efficacy (RCE). In addition, in comprehensively improving RCE and FEV%, and RCE and C-reactive protein, Huangqi injection (HQ) +WM was associated with preferable effects. Similarly, Xixinnao injection + WM, Reduning injection (RDN) +WM, and HQ+WM had a favorable effect on RCE and PaO. The effect of RDN+WM was favorable in all outcomes except RCE. The safety of CHIs needs to be further assessed.
Based on this NMA, DH+WM, HQ+WM, and RDN+WM were potential optimal therapies in AECOPD and their safety should be strictly monitored.
慢性阻塞性肺疾病急性加重(AECOPD)给全球医疗系统带来了巨大的经济负担。中药注射剂(CHIs)被广泛用于治疗AECOPD。在本研究中,我们使用网状Meta分析(NMA)来检验CHIs治疗AECOPD的疗效。
从关于CHIs联合西药(WM)对比单纯WM的随机对照试验(RCTs)的电子数据库中进行文献检索。分别采用WinBUGS 1.4.3和STATA 12.0进行计算和绘制图表。
我们纳入了155项RCTs,共13218例患者。结果显示,丹红注射液(DH)+WM在临床有效率(RCE)方面具有最大的治疗潜力。此外,在综合改善RCE和第一秒用力呼气容积百分比(FEV%),以及RCE和C反应蛋白方面,黄芪注射液(HQ)+WM具有较好的效果。同样,细辛脑注射液+WM、热毒宁注射液(RDN)+WM以及HQ+WM对RCE和动脉血氧分压(PaO)有良好效果。RDN+WM除RCE外,在所有结局指标上效果良好。CHIs的安全性需要进一步评估。
基于本NMA,DH+WM、HQ+WM和RDN+WM是AECOPD潜在的最佳治疗方案,其安全性应受到严格监测。